Clinical Trial Update

Summary by AI BETAClose X

CRISM Therapeutics Corporation has announced the successful completion of the Site Initiation Visit at its lead NHS clinical trial site, paving the way for patient recruitment in the coming weeks for its Phase II study. This study will evaluate irinotecan ChemoSeed®, the company's proprietary implantable drug delivery technology designed for sustained, localised delivery of irinotecan directly into the tumour margin following glioblastoma resection.

Disclaimer*

UK 100

Latest directors dealings